• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Superconnector
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    Imperative Care Completes Initial Closing of Series E Financing for up to $150 Million; Shacey Petrovic Appointed to Vice Chair, Board of Directors

    7/25/24 8:00:00 AM ET
    $EXAS
    $PODD
    Medical Specialities
    Health Care
    Medical/Dental Instruments
    Health Care
    Get the next $EXAS alert in real time by email

    Financing Fuels the Company's Hypergrowth to Make Elevated Care Accessible to More Patients

    Petrovic's Appointment Positions Imperative Care for Long Term Success and Scale

    Imperative Care, Inc., a medical technology company developing connected innovations to elevate care for people affected by stroke and other ischemic diseases, today announced the initial close of an oversubscribed Series E financing.

    The financing was led by Ally Bridge Group with participation from other existing investors, including D1 Capital Partners, AMED Ventures, Bain Capital Life Sciences, Rock Springs Capital Management LP, Innovatus Capital Partners, LLC and Pura Vida Investments. The financing also included participation from new investors, including Catalio Capital Management, LP, HealthCor Family Office, Montreux Growth Partners, and INTAI Technology Corp.

    "We are grateful for the continued support of our existing investors and welcome our new investors who share our vision for leadership in stroke and vascular thrombectomy," said Fred Khosravi, Chairman and CEO of Imperative Care. "This latest financing fuels our hypergrowth strategy as we work to make better care accessible to more patients. We will continue to invest in novel technologies and clinical evidence to measure the impact of these technologies on patient outcomes."

    "As investors in Imperative Care since the company's Series C financing in December 2019, we have been impressed with the dramatic progress the company has made on many fronts, including treating more than 45,000 patients with life-saving technologies," said Ally Bridge founder and CEO Frank Yu, who has also served as a Director on the Imperative Care Board since 2019. "We are excited to support the next stage of Imperative Care's success, as the company strengthens its position for treating ischemic stroke and prepares to make a major contribution to the treatment of peripheral vascular disease."

    After the initial closing and subject to the discretion of the Company, there may be additional closings of this Series E financing, raising up to $150 million in total.

    Appointment of Shacey Petrovic to Vice Chair, Board of Directors

    The company also announced the appointment of Shacey Petrovic to the newly created position of Vice Chair of its Board of Directors. Petrovic joined the Imperative Care Board in 2023. In the role of Vice Chair, Petrovic will focus on strategies to scale the company with the goal of bringing life-changing technologies to more patients suffering from stroke and other devastating vascular diseases.

    Petrovic also serves on the Boards of Exact Sciences (NASDAQ:EXAS), Ambu A/S (OTC US: AMBBY) and Axena Health. Previously, Petrovic served on the board and was President and CEO of Insulet Corporation (NASDAQ:PODD), a diabetes technology company. Under her leadership, Insulet grew to serve hundreds of thousands of people with diabetes across the globe.

    "It has been a privilege to benefit from Shacey's business acumen and strategic mastery as we position Imperative Care for long term success and scale," Khosravi said. "On behalf of our Board of Directors, I would like to congratulate Shacey on her appointment to Vice Chair as we continue to build the thrombectomy company of the future with the patient at the center."

    "I am excited to step into this new leadership role as Imperative Care accelerates its work to deliver impactful innovations to patients at the most tenuous moments of their lives," said Petrovic. "My experience serving on the Imperative Care Board has been quite inspirational as the company engineers solutions to some of the greatest challenges in medicine through medtech and digital health innovations."

    About Imperative Care, Inc.

    Imperative Care is a commercial-stage medical technology company researching and developing connected innovations to elevate care for people affected by devastating vascular diseases such as stroke and pulmonary embolism. The company is focused on addressing specific gaps in treatment and care to make an impact across the entire patient journey. Imperative Care is based in Campbell, Calif. https://imperativecare.com

    Legal Disclaimer / Forward-Looking Statements

    This press release is not an offer to sell securities or a solicitation of an offer to buy any securities, and may not be relied upon in connection with the purchase or sale of any company security. This release may contain forward-looking statements regarding plans for future financing, projected business performance, future innovations and improvement of patient outcomes. Such statements are forward-looking statements and there can be no assurance that the results stated or implied by these forward-looking statements will actually be realized or achieved by the company. Forward-looking statements may be based on management assumptions that could prove to be wrong. The company's predictions may not be realized for a variety of reasons as the company's business is subject to substantial risks and potential events beyond its control that could cause material differences between predicted and actual results.

    View source version on businesswire.com: https://www.businesswire.com/news/home/20240725822876/en/

    Get the next $EXAS alert in real time by email

    Crush Q3 2025 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $EXAS
    $PODD

    CompanyDatePrice TargetRatingAnalyst
    Insulet Corporation
    $PODD
    11/19/2025$400.00Neutral → Buy
    UBS
    Insulet Corporation
    $PODD
    10/21/2025$370.00Buy
    Stifel
    Insulet Corporation
    $PODD
    9/8/2025$365.00Outperform
    Oppenheimer
    Insulet Corporation
    $PODD
    6/16/2025$365.00Buy
    Truist
    Insulet Corporation
    $PODD
    5/30/2025$380.00Buy
    Goldman
    Insulet Corporation
    $PODD
    5/13/2025$350.00Peer Perform → Outperform
    Wolfe Research
    Insulet Corporation
    $PODD
    4/29/2025Outperform → Peer Perform
    Wolfe Research
    Exact Sciences Corporation
    $EXAS
    4/10/2025$60.00Outperform
    Mizuho
    More analyst ratings

    $EXAS
    $PODD
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    EVP, GM, Screening Orville Jacob A sold $375,000 worth of shares (5,000 units at $75.00), decreasing direct ownership by 18% to 23,237 units (SEC Form 4)

    4 - EXACT SCIENCES CORP (0001124140) (Issuer)

    11/21/25 5:30:06 PM ET
    $EXAS
    Medical Specialities
    Health Care

    SVP, General Counsel & Sec Herriott James sold $70,000 worth of shares (1,000 units at $70.00), decreasing direct ownership by 8% to 11,585 units (SEC Form 4)

    4 - EXACT SCIENCES CORP (0001124140) (Issuer)

    11/21/25 5:30:03 PM ET
    $EXAS
    Medical Specialities
    Health Care

    SVP, General Counsel & Sec Herriott James sold $105,120 worth of shares (1,500 units at $70.08), decreasing direct ownership by 11% to 12,585 units (SEC Form 4)

    4 - EXACT SCIENCES CORP (0001124140) (Issuer)

    11/6/25 5:29:37 PM ET
    $EXAS
    Medical Specialities
    Health Care

    $EXAS
    $PODD
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    $EXAS
    $PODD
    SEC Filings

    View All

    Insulet upgraded by UBS with a new price target

    UBS upgraded Insulet from Neutral to Buy and set a new price target of $400.00

    11/19/25 8:31:06 AM ET
    $PODD
    Medical/Dental Instruments
    Health Care

    Stifel resumed coverage on Insulet with a new price target

    Stifel resumed coverage of Insulet with a rating of Buy and set a new price target of $370.00

    10/21/25 7:21:42 AM ET
    $PODD
    Medical/Dental Instruments
    Health Care

    Oppenheimer resumed coverage on Insulet with a new price target

    Oppenheimer resumed coverage of Insulet with a rating of Outperform and set a new price target of $365.00

    9/8/25 8:52:38 AM ET
    $PODD
    Medical/Dental Instruments
    Health Care

    SEC Form DEFA14A filed by Exact Sciences Corporation

    DEFA14A - EXACT SCIENCES CORP (0001124140) (Filer)

    11/20/25 5:23:44 PM ET
    $EXAS
    Medical Specialities
    Health Care

    SEC Form DEFA14A filed by Exact Sciences Corporation

    DEFA14A - EXACT SCIENCES CORP (0001124140) (Filer)

    11/20/25 4:56:30 PM ET
    $EXAS
    Medical Specialities
    Health Care

    SEC Form DEFA14A filed by Exact Sciences Corporation

    DEFA14A - EXACT SCIENCES CORP (0001124140) (Filer)

    11/20/25 4:55:27 PM ET
    $EXAS
    Medical Specialities
    Health Care

    $EXAS
    $PODD
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Quanterix Announces Board and Leadership Changes to Support Next Stage of Growth

    Appoints Garret Hampton and Alan Sachs to the Board Appoints William Donnelly as Executive Chair of the Board and Jeffrey Elliott as Lead Independent Director Quanterix Corporation ("Quanterix" or the "Company") (NASDAQ:QTRX), a company transforming healthcare by accelerating biomarker breakthroughs from discovery to diagnostics, today announced a series of leadership and governance enhancements designed to support the Company's next phase of growth. These changes include the appointment of two highly accomplished life sciences executives, Garret Hampton, Ph.D., and Alan Sachs, M.D., Ph.D., to the Company's Board of Directors, effective immediately. Dr. Hampton most recently served as

    11/20/25 4:15:00 PM ET
    $EXAS
    $IDYA
    $ILMN
    Medical Specialities
    Health Care
    Biotechnology: Pharmaceutical Preparations
    Industrial Machinery/Components

    Insulet Outlines Long-Term Strategy to Drive Growth and Value Creation at 2025 Investor Day

    Company announces strong long-range financial outlook for 2025–2028 Introduces next-generation innovation pipeline to transform diabetes care Insulet Corporation (NASDAQ:PODD) ("Insulet" or the "Company"), the global leader in tubeless insulin pump technology with its Omnipod® brand of products, today hosted its 2025 Investor Day at the Company's global headquarters in Acton, Massachusetts. During the event, Insulet's executive team outlined the strategic plan and innovation roadmap that is designed to extend its leadership in the fast-growing and significantly underpenetrated global markets for automated insulin delivery (AID) for type 1 and type 2 diabetes, as well as its financ

    11/20/25 12:30:00 PM ET
    $PODD
    Medical/Dental Instruments
    Health Care

    Abbott to acquire Exact Sciences, a leader in large and fast-growing cancer screening and precision oncology diagnostics segments

    Acquisition adds a new growth vertical to Abbott's already high single-digit growth profile, gaining leadership in the fast-growing $60 billion U.S. cancer screening and precision oncology diagnostics segmentsAcquisition will uniquely position Abbott to transform cancer care, advancing earlier detection and optimizing treatment and monitoring to help millions more people live healthier livesExact Sciences' product lines feature advanced cancer screening and diagnostic solutions, including the market-leading Cologuard® and Oncotype DX® tests, and cutting-edge liquid biopsy tests for multi-cancer early detection and molecular residual disease testingAcquisition will be immediately accretive to

    11/20/25 7:30:00 AM ET
    $ABT
    $EXAS
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Medical Specialities

    $EXAS
    $PODD
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    President and CEO Conroy Kevin T bought $1,001,325 worth of shares (19,500 units at $51.35), increasing direct ownership by 2% to 1,074,191 units (SEC Form 4)

    4 - EXACT SCIENCES CORP (0001124140) (Issuer)

    11/13/24 12:56:28 PM ET
    $EXAS
    Medical Specialities
    Health Care

    EVP, CFO & Treasurer Chadwick Ana Maria bought $20,600 worth of shares (100 units at $206.00), increasing direct ownership by 0.76% to 13,314 units (SEC Form 4)

    4 - INSULET CORP (0001145197) (Issuer)

    8/29/24 4:17:26 PM ET
    $PODD
    Medical/Dental Instruments
    Health Care

    SEC Form 4: Singh Prem bought $169 worth of shares (1 units at $168.92), increasing direct ownership by 0.02% to 4,032 units

    4 - INSULET CORP (0001145197) (Issuer)

    9/21/23 4:48:23 PM ET
    $PODD
    Medical/Dental Instruments
    Health Care

    $EXAS
    $PODD
    Leadership Updates

    Live Leadership Updates

    View All

    Quanterix Announces Board and Leadership Changes to Support Next Stage of Growth

    Appoints Garret Hampton and Alan Sachs to the Board Appoints William Donnelly as Executive Chair of the Board and Jeffrey Elliott as Lead Independent Director Quanterix Corporation ("Quanterix" or the "Company") (NASDAQ:QTRX), a company transforming healthcare by accelerating biomarker breakthroughs from discovery to diagnostics, today announced a series of leadership and governance enhancements designed to support the Company's next phase of growth. These changes include the appointment of two highly accomplished life sciences executives, Garret Hampton, Ph.D., and Alan Sachs, M.D., Ph.D., to the Company's Board of Directors, effective immediately. Dr. Hampton most recently served as

    11/20/25 4:15:00 PM ET
    $EXAS
    $IDYA
    $ILMN
    Medical Specialities
    Health Care
    Biotechnology: Pharmaceutical Preparations
    Industrial Machinery/Components

    Insulet Announces Appointment of Robert L. Huffines to its Board of Directors

    Insulet Corporation (NASDAQ:PODD) (Insulet or the Company), the global leader in tubeless insulin pump technology with its Omnipod® brand of products, today announced the appointment of Robert ("Robbie") L. Huffines, a former Global Chair of Investment Banking at JP Morgan Chase & Co., to the Company's board of directors, effective October 31, 2025. Mr. Huffines joins the board as an independent director and will serve on the board's Audit Committee. "We are honored to welcome Robbie to Insulet's Board of Directors," said Timothy Scannell, Chairman of the Board. "Robbie brings more than three decades of distinguished experience advising healthcare companies at one of the world's leading f

    10/23/25 7:00:00 AM ET
    $PODD
    Medical/Dental Instruments
    Health Care

    Insulet to Host Investor Day on November 20, 2025

    Insulet Corporation (NASDAQ:PODD) (Insulet or the Company), the global leader in tubeless insulin pump technology with its Omnipod® brand of products, will host an Investor Day at the Company's Acton, Massachusetts headquarters on Thursday, November 20, 2025. The Investor Day will include presentations from the management team highlighting the Company's longer-term strategic priorities, including market opportunities, innovation roadmap, as well as its longer-term financial outlook. Manufacturing tours will be available following the conclusion of the formal presentations, which are expected to begin at 9:00 a.m. (ET) and conclude at approximately 12:30 p.m. (ET). The Company invites in

    10/10/25 7:00:00 AM ET
    $PODD
    Medical/Dental Instruments
    Health Care

    $EXAS
    $PODD
    Financials

    Live finance-specific insights

    View All

    Abbott to acquire Exact Sciences, a leader in large and fast-growing cancer screening and precision oncology diagnostics segments

    Acquisition adds a new growth vertical to Abbott's already high single-digit growth profile, gaining leadership in the fast-growing $60 billion U.S. cancer screening and precision oncology diagnostics segmentsAcquisition will uniquely position Abbott to transform cancer care, advancing earlier detection and optimizing treatment and monitoring to help millions more people live healthier livesExact Sciences' product lines feature advanced cancer screening and diagnostic solutions, including the market-leading Cologuard® and Oncotype DX® tests, and cutting-edge liquid biopsy tests for multi-cancer early detection and molecular residual disease testingAcquisition will be immediately accretive to

    11/20/25 7:30:00 AM ET
    $ABT
    $EXAS
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Medical Specialities

    Insulet Reports Third Quarter 2025 Results

    Raises Full Year Revenue and Margin Guidance Insulet Corporation (NASDAQ:PODD) (Insulet or the Company), the global leader in tubeless insulin pump technology with its Omnipod® brand of products, today announced its financial results for the three months ended September 30, 2025. Third Quarter Financial Highlights: Revenue of $706.3 million, increased 29.9%, or 28.2% in constant currency1, and exceeded the high end of the Company's guidance range of 22% - 25% at constant currency rates Total Omnipod revenue of $699.2 million, rose 31.0%, or 29.3% in constant currency U.S. Omnipod revenue of $497.1 million, grew 25.6% International Omnipod revenue of $202.1 million, advanced 46.5%,

    11/6/25 6:30:00 AM ET
    $PODD
    Medical/Dental Instruments
    Health Care

    Exact Sciences Announces Third Quarter 2025 Results

    Reports record revenue, raises full-year guidance, generates record cash from operations Third quarter and recent highlights Delivered record total third quarter revenue of $851 million, an increase of 20% on a reported and core revenue basis, including Screening revenue of $666 million and Precision Oncology revenue of $184 million Raised full-year 2025 revenue and adjusted EBITDA guidance midpoints by $78 million and $10 million, respectively Generated record cash from operations and free cash flow Launched Cancerguard®, the company's multi-cancer early detection test, for patients in the United States Exact Sciences Corp. (NASDAQ:EXAS), a leading provider of cancer scree

    11/3/25 4:05:00 PM ET
    $EXAS
    Medical Specialities
    Health Care

    $EXAS
    $PODD
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13G filed by Exact Sciences Corporation

    SC 13G - EXACT SCIENCES CORP (0001124140) (Subject)

    11/13/24 2:58:53 PM ET
    $EXAS
    Medical Specialities
    Health Care

    Amendment: SEC Form SC 13G/A filed by Insulet Corporation

    SC 13G/A - INSULET CORP (0001145197) (Subject)

    11/12/24 12:53:28 PM ET
    $PODD
    Medical/Dental Instruments
    Health Care

    Amendment: SEC Form SC 13G/A filed by Exact Sciences Corporation

    SC 13G/A - EXACT SCIENCES CORP (0001124140) (Subject)

    11/8/24 10:52:39 AM ET
    $EXAS
    Medical Specialities
    Health Care